-
-
-
The Expanding Benefits of GLP-1 Medicines
Diabetes
Discover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
Top 10 Best-Selling Drugs in Q1 2025
Market Trend
Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
-
-
-
-
蒙阴县|
衢州市|
永吉县|
淳安县|
鄱阳县|
龙江县|
叶城县|
江达县|
武隆县|
丹阳市|
教育|
合山市|
永春县|
车险|
罗甸县|
五莲县|
怀来县|
县级市|
旌德县|
日喀则市|
莲花县|
温宿县|
宁国市|
桓仁|
济南市|
靖州|
大田县|
德钦县|
阿尔山市|
嘉义市|
平邑县|
西畴县|
怀仁县|
成都市|
阿瓦提县|
宜都市|
武功县|
霍林郭勒市|
平安县|
新昌县|
望城县|